PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Antiviral - Market size and forecast 2018-2023 Antibacterial - Market size and forecast 2018-2023 Antifungal - Market size and forecast 2018-2023 Antiparasitic - Market size and forecast 2018-2023 Market opportunity by application PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increase in R&D of therapeutic vaccines Increased disease diagnostic modalities PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Gilead Sciences, Inc. GlaxoSmithKline plc Merck & Co Inc. Pfizer Inc. Sanofi PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Application - Market share 2018-2023 (%) Exhibit 18: Comparison by application Exhibit 19: Antiviral - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Antiviral - Year-over-year growth 2019-2023 (%) Exhibit 21: Antibacterial - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Antibacterial - Year-over-year growth 2019-2023 (%) Exhibit 23: Antifungal - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Antifungal - Year-over-year growth 2019-2023 (%) Exhibit 25: Antiparasitic - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Antiparasitic - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by application Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Some of the late-stage molecules Exhibit 42: Impact of drivers and challenges Exhibit 43: Therapeutic vaccines Exhibit 44: Some of the recent POC diagnostics approvals in the US Exhibit 45: Some of the recently approved combination therapy drugs Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Gilead Sciences, Inc. - Vendor overview Exhibit 52: Gilead Sciences, Inc. - Business segments Exhibit 53: Gilead Sciences, Inc. - Organizational developments Exhibit 54: Gilead Sciences, Inc. - Geographic focus Exhibit 55: Gilead Sciences, Inc. - Segment focus Exhibit 56: Gilead Sciences, Inc. - Key offerings Exhibit 57: GlaxoSmithKline plc - Vendor overview Exhibit 58: GlaxoSmithKline plc - Business segments Exhibit 59: GlaxoSmithKline plc - Organizational developments Exhibit 60: GlaxoSmithKline plc - Geographic focus Exhibit 61: GlaxoSmithKline plc - Segment focus Exhibit 62: GlaxoSmithKline plc - Key offerings Exhibit 63: GlaxoSmithKline plc - Key offerings Exhibit 64: Merck & Co Inc. - Vendor overview Exhibit 65: Merck & Co Inc. - Business segments Exhibit 66: Merck & Co Inc. - Organizational developments Exhibit 67: Merck & Co Inc. - Geographic focus Exhibit 68: Merck & Co Inc. - Segment focus Exhibit 69: Merck & Co Inc. - Key offerings Exhibit 70: Pfizer Inc. - Vendor overview Exhibit 71: Pfizer Inc. - Business segments Exhibit 72: Pfizer Inc. - Organizational developments Exhibit 73: Pfizer Inc. - Geographic focus Exhibit 74: Pfizer Inc. - Segment focus Exhibit 75: Pfizer Inc. - Key offerings Exhibit 76: Sanofi - Vendor overview Exhibit 77: Sanofi - Business segments Exhibit 78: Sanofi - Organizational developments Exhibit 79: Sanofi - Geographic focus Exhibit 80: Sanofi - Segment focus Exhibit 81: Sanofi - Key offerings Exhibit 82: Validation techniques employed for market sizing Exhibit 83: Definition of market positioning of vendors

Gilead Sciences, Inc. GlaxoSmithKline plc Merck & Co Inc. Pfizer Inc. Sanofi